Genetic Signatures appoints Allison Rossiter as CEO

Genetic Signatures Limited (ASX: $GSS) has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, as CEO. Ms Rossiter, who has extensive global experience in the diagnostics industry, will be based in Sydney, Australia. She joins Genetic Signatures at a pivotal time as the company is about to launch its first FDA-cleared 3base product, the EasyScreenTM Gastrointestinal Parasite Detection Kit, into the US market. Ms Rossiter will commence her role as CEO of Genetic Signatures no later than the end of September 2024.

Allison Rossiter's vision for Genetic Signatures

I am over the moon to be able to bring my extensive and proven commercial acumen as well as my knowledge of product development, regulatory processes and clinical value to a company such as Genetic Signatures. It is an incredibly exciting time for GSS and I am honoured to take on this role at such a pivotal time for the company and the employees.

Genetic Signatures' outlook with new CEO appointment

Genetic Signatures has appointed Allison Rossiter as CEO, bringing extensive global experience in the diagnostics industry. Ms Rossiter's appointment comes at a crucial time as the company prepares to launch its first FDA-cleared 3base product into the US market. With her background in leading efforts for diagnostics tests for the SARS-CoV-2 virus and achieving significant growth in previous roles, Ms Rossiter is well-placed to lead Genetic Signatures' global expansion. The company's focus on commercializing its products and technology onto the global stage aligns with Ms Rossiter's vision and expertise. Genetic Signatures aims to leverage its strong COVID-19 related sales and growing interest in its gastroenteritis products to further advance its 3base technology for infectious disease screening, including antibiotic resistant bacteria, sexually transmitted infections, meningitis, and mosquito-borne viral diseases.